Program
Travoprost
Also written as “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, “Travoprost 0.004% / Timolol maleate 0.5%” and “Travoprost 0.004% ophthalmic solution”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Glaucoma, Angle-Closure · Low Tension Glaucoma · Hydrophthalmos, led by 5 companies.
Drug pageTravoprost: every studyMany companies study it; this page follows only the 63 they lead. All 80 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alconits history only | 520 open or running | phase 4since May 28, 2003 | Jan 3, 2003 | none ahead |
| Glaukosits history only | 72 open or running | phase 4since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Ocular Therapeutixits history only | 20 open or running | phase 3since Sep 21, 2016 | Dec 4, 2014 | none ahead |
| Laboratorios Sophia S.A de C.V. | 10 open or running | phase 1since May 23, 2019 | May 23, 2019 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Feb 16, 2009 | Feb 16, 2009 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Laboratorios Sophia S.A de C.V. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2019First study: phase 1 study in GlaucomaFirst studyNCT03965052 · 24 enrolled · Mexico
TargetBeta
“Prostanoid FP receptor agonist”ChEMBL 37, by rule
Other programs on PTGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| AGN-193408 | AbbVie | phase 2 | 1 |
Studies
The one study Laboratorios Sophia S.A de C.V. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03965052Glaucoma · Mexico | 1 | Completed | Jul 2, 2019 | 24 |
How it is read
Names in the registry
- “Travoprost”, 6 entries
- “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, 5 entries
- “Travoprost 0.004% / Timolol maleate 0.5%”, 2 entries
- “Travoprost 0.004% ophthalmic solution”, 2 entries
- “Travoprost ophthalmic solution, 0.004%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 42 studies
- Glaucoma, 20 studies
- Glaucoma, Angle-Closure, 2 studies
- Low Tension Glaucoma, 1 study
- Hydrophthalmos, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.